AbbVie Total Assets 2010-2019 | ABBV

AbbVie total assets from 2010 to 2019. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • AbbVie total assets for the quarter ending June 30, 2019 were $57.142B, a 7.3% decline year-over-year.
  • AbbVie total assets for 2018 were $59.352B, a 16.15% decline from 2017.
  • AbbVie total assets for 2017 were $70.786B, a 7.09% increase from 2016.
  • AbbVie total assets for 2016 were $66.099B, a 24.6% increase from 2015.
AbbVie Annual Total Assets
(Millions of US $)
2018 $59,352
2017 $70,786
2016 $66,099
2015 $53,050
2014 $27,513
2013 $29,198
2012 $27,008
2011 $19,521
2010 $21,135
2009 $0
AbbVie Quarterly Total Assets
(Millions of US $)
Q2 2019 $57,142
Q1 2019 $56,769
Q4 2018 $59,352
Q3 2018 $66,164
Q2 2018 $61,641
Q1 2018 $69,342
Q4 2017 $70,786
Q3 2017 $68,840
Q2 2017 $66,994
Q1 2017 $65,664
Q4 2016 $66,099
Q3 2016 $66,626
Q2 2016 $67,211
Q1 2016 $53,720
Q4 2015 $53,050
Q3 2015 $54,832
Q2 2015 $53,855
Q1 2015 $26,699
Q4 2014 $27,513
Q3 2014 $28,454
Q2 2014 $29,045
Q1 2014 $28,657
Q4 2013 $29,198
Q3 2013 $28,252
Q2 2013 $27,910
Q1 2013 $27,169
Q4 2012 $27,008
Q3 2012 $22,730
Q2 2012 $17,710
Q1 2012 $18,962
Q4 2011 $19,521
Q3 2011 $0
Q2 2011 $0
Q1 2011 $0
Q4 2010 $21,135
Q4 2009 $0
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $105.963B $32.753B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $343.382B 14.95
Roche Holding AG (RHHBY) Switzerland $244.080B 0.00
Merck (MRK) United States $214.995B 17.68
Pfizer (PFE) United States $201.939B 11.89
Novartis AG (NVS) Switzerland $197.897B 17.03
Novo Nordisk (NVO) Denmark $122.852B 21.71
AstraZeneca (AZN) United Kingdom $117.046B 22.65
Sanofi (SNY) France $112.486B 13.82
Eli Lilly (LLY) United States $110.397B 20.60
GlaxoSmithKline (GSK) United Kingdom $103.061B 12.95
Bristol-Myers Squibb (BMY) United States $81.903B 11.62
Bayer (BAYRY) Germany $68.710B 10.01
H Lundbeck (HLUYY) Denmark $6.906B 9.97